The role of IVIg treatment in severe pemphigus vulgaris

S. Baum*, A. Scope, A. Barzilai, E. Azizi, H. Trau

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: High-dose intravenous immunoglobulin (IVIg) has become a part of the treatment armentarium in pemphigus vulgaris (PV). Some consider IVIg as an adjuvant steroid sparing agent in PV, while others as disease modifying that can be used as monotherapy. Methods: We report our experience with a series of 12 PV patients with severe disease treated with IVIg as an adjuvant therapy. Results: Ten of 12 patients (83%) showed response to six cycles of IVIg, six (50%) having complete remission and four (33%) having a partial response. This response rate is concordant with previous reports. The therapy was well tolerated. In all 12 patients, treatment with IVIg allowed a gradual reduction of prednisone dose compared with baseline levels. Conclusion: IVIg treatment was beneficial as asteroid sparing agent in our series of patients with severe PV.

Original languageEnglish
Pages (from-to)548-552
Number of pages5
JournalJournal of the European Academy of Dermatology and Venereology
Issue number5
StatePublished - May 2006


  • Intravenous immunoglobulin treatment
  • Severe pemphigus vulgaris
  • Steroid sparing treatment


Dive into the research topics of 'The role of IVIg treatment in severe pemphigus vulgaris'. Together they form a unique fingerprint.

Cite this